Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRKAR1A
REST API REST API
Homo sapiens
PRKAR1A is differentially expressed in 346 experiments: 138 organism parts: heart, liver, ... (136 more);, 199 disease states: normal, control, ... (197 more);, 105 cell types 417 cell lines 45 compound treatments and 84 other conditions.
Synonyms PRKAR1, TSE1
Orthologs KAP0_BOVIN (Bos taurus)   ENSCING00000002597 (Ciona intestinalis)   Prkar1a (Mus musculus)   F1M448_RAT (Rattus norvegicus)   KAP0_CHICK (Gallus gallus)   BCY1 (Saccharomyces cerevisiae)   prkar1aa (Danio rerio)   Pka-R1 (Drosophila melanogaster)   ENSXETG00000011197 (Xenopus laevis)   ENSXETG00000018294 (Xenopus laevis)   PRKAR1A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, mesoderm formation, regulation of phosphorylation, protein binding, cAMP binding, protein complex, regulation of catalytic activity, blood coagulation, cAMP-dependent protein kinase complex, cAMP-dependent protein kinase regulator activity, neuromuscular junction, activation of phospholipase C activity, nucleotide binding, transmembrane transport, regulation of transcription from RNA polymerase II promoter, signal transduction, ubiquitin protein ligase binding, energy reserve metabolic process, water transport, nerve growth factor receptor signaling pathway, regulation of insulin secretion, regulation of protein phosphorylation, intracellular signal transduction, activation of protein kinase A activity, cellular response to glucagon stimulus
InterPro Term cAMP/cGMP_kin, cAMP_dep_PK_reg_su_I/II_a/b, cAMP_dep_PK_reg_su, cNMP-bd_dom
UniProt Accession B2R5T5, Q96P62, P10644
Gene-Disease Assocation MYXOMA, INTRACARDIAC, THYROID CARCINOMA, PAPILLARY, PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1, ACRODYSOSTOSIS WITH HORMONE RESISTANCE; ADOHR, CARNEY COMPLEX, TYPE 1; CNC1
Search EB-eye ENSG00000108946
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
BT20
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
PC3
2
E-MEXP-2034, E-GEOD-14464
SNU16
2
E-MTAB-37, E-GEOD-15460
411 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (50 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
dendritic cell
2
E-GEOD-360, E-GEOD-3982
stromal cell
2
E-MEXP-2034, E-GEOD-1460
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
whole blood
2
E-GEOD-3026, E-MTAB-25
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (73 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-GEOD-2514, E-MTAB-62
sarcoma
2
E-GEOD-2719, E-MTAB-37
extranodal NK/T-cell lymphoma
2
E-GEOD-19067, E-TABM-702
Classic-KS, HIV-, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
193 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
glutamine
2
E-MEXP-1335, E-MEXP-941
glucose
1
E-MEXP-941
4OH-tamoxifen
1
E-GEOD-2292
resveratrol
1
E-TABM-782
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
39 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
41
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-4619, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (11 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (18 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (46 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.403 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM